Is Ligand Pharmaceuticals Incorporated (LGND) a Buy, Sell, or Hold?
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$298.0485 USD
-$2.92 (-0.97%)
- Volume
- 94.19K
- Average Volume
- 331.69K
- Market Capitalization
- $5.97B
- P/E Ratio
- 38.02
- Dividend Yield
- 0.00%
- Price Target
- $332.00
- Year High
- $326.63
- Year Low
- $123.66
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $21.28
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Todd C. Davis |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | LGND |
| CUSIP | 53220K504 |
| CIK | 0000886163 |
| Web | https://www.ligand.com |
| Phone | 858 550 7500 |
| Currency | USD |
| Employees | 47 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.45 |
| Payout Ratio | 0.00 |
| Current Ratio | 21.28 |
| Quick Ratio | 20.95 |
| Cash Ratio | 2.83 |
Sales & Book Value
| Annual Sales | $268.09M |
| Price / Sales | 21.76 |
| Cash Flow | 6.18 |
| Price / Cash Flow | 48.58 |
| Price / Book | 5.94 |
Price Target and Rating
| Average Stock Price Forecast | $332.00 |
| High Stock Price Forecast | $340.00 |
| Low Stock Price Forecast | $289.00 |
| Forecast Upside/Downside | -10.23% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 18 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $6.13 |
| Trailing P/E Ratio | 38.02 |
| PEG Ratio | 0.03 |
| P/E Growth | 0.03 |
| Net Income | $124.45M |
| Net Margin | 55.95% |
| Pretax Margin | 67.36% |
| Return on Equity | 16.19% |
| Return on Assets | 10.02% |
Financials Score
| AltmanZ Score | 8.59 |
| Piotroski Score | 6.00 |
| Working Capital | 824.75M |
| Total Assets | 1.53B |
| Ebit | 187.78M |
| Market Cap | 6.07B |
| Total Liabilities | 534.78M |
Poll Results
About Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect ... children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
2026-07-14 09:00:00
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.
XOMA Royalty Announces Closing of Its Acquisition by Ligand
2026-07-14 09:00:00
EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
2026-07-12 22:44:47
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now
Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator
2026-06-30 21:40:10
Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.
Ligand Announces Closing of Convertible Senior Notes Offering
2026-06-25 16:01:00
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.00% convertible senior notes due 2031 (the “notes”).
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
2026-06-23 04:00:00
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
2026-06-22 07:00:00
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.
Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?
2026-06-14 07:00:01
Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.
Frequently Asked Questions
-
What is the current Ligand Pharmaceuticals Incorporated (LGND) stock price?
-
Ligand Pharmaceuticals Incorporated(NASDAQ:LGND) stock price is $298.0485 in the last trading session. During the trading session, LGND stock reached the peak price of $326.63 while $123.66 was the lowest point it dropped to. The percentage change in LGND stock occurred in the recent session was --0.97% while the dollar amount for the price change in LGND stock was -$-2.92.
-
LGND's industry and sector of operation?
-
The NASDAQ listed LGND is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LGND?
-
Keith Marschke | Senior Vice President of Biology & Scientific Affairs
Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol
Karen R. Reeves | Senior Vice President of Investments & Head of Clinical Strategy
Paul J. Hadden | Senior Vice President of Investments & Business Development
Richard Baxter | Senior VP of Investment Operations -
How many employees does LGND have?
-
Number of LGND employees currently stands at 47. LGND operates from 5980 Horton Street, Jupiter, FL 94608, US.
-
Link for LGND official website?
-
Official Website of LGND is: https://www.ligand.com
-
How do I contact LGND?
-
LGND could be contacted at phone #858 550 7500 and can also be accessed through its website. LGND operates from 5980 Horton Street, Jupiter, FL 94608, US.
-
How many shares of LGND are traded daily?
-
The average number of LGND shares traded daily for last 3 months was 331.69K.
-
What is the market cap of LGND currently?
-
The market value of LGND currently stands at $5.97B with its latest stock price at $298.0485